CALL US: 1-352-733-0111

A Phase 3b Continuation study of the Safety and Efficacy of PEGylated Recombinant Factor VIII (PEG-rFVIII; BAX 855) in Prophylaxis of Bleeding in Previously Treated Patients with Severe Hemophilia A


1. To determine the safety of BAX 855 based on incidence of neutralizing inhibitor development. 2. To determine the efficacy of BAX 855 based on ABR as determined by development of spontaneous bleeds (bleeds not associated with trauma).


inhibitor, BAX855, bleeds, neutralizing, trauma

Principal Investigator

Tung Wynn, M.D.



Contact Information

Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at

Other Resources

  • Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams